强化热疗辅助小剂量顺铂化疗联合放疗治疗局部晚期非小细胞肺癌的疗效观察  

Effect of intensive hyperthermia combined with low-dose cisplatin plus radiotherapy in the treatment of patients with locally advanced NSCLC

作　　者：陈鲁青 王敏 周万里 相法军 韩德娟 孙振友 刘国威 高洪盛 Chen Luqing;Wang Min;Zhou Wanli;Xiang Fajun;Han Dejuan;Sun Zhenyou;Liu Guowei;Gao Hongsheng(Department of Radiotherapy,the Second People's Hospital of Weifang,Weifang,Shandong 261041,China)

机构地区：[1]潍坊市第二人民医院放疗科,山东省261041

出　　处：《中国基层医药》2020年第3期322-325,共4页Chinese Journal of Primary Medicine and Pharmacy

摘　　要：目的观察强化热疗辅助小剂量顺铂化疗联合放疗对局部晚期非小细胞肺癌(NSCLC)患者的疗效及安全性。方法选取潍坊市第二人民医院2012年1月至2015年12月收治的局部晚期NSCLC患者104例,采用随机数字表法分为对照组(52例)和观察组(52例),分别采用小剂量顺铂联合放疗和在此基础上加用强化热疗辅助治疗;比较两组客观缓解率(ORR)、疾病控制率(DCR)、中位总生存时间(OS)、中位无进展生存时间(PFS)、治疗前后卡氏(KPS)评分、凝血功能指标[凝血酶原时间(PT)、活化部分凝血活酶时间(APTT)、纤维蛋白原(FIB)、D-D聚体(D-D)]、肿瘤标志物[血清癌胚抗原(CEA)、糖类抗原125(CA125)、细胞角蛋白19可溶性片段21-1(CYFRA21-1)]水平及毒副作用发生率。结果观察组DCR显著高于对照组(86.54%比69.23%,χ2=8.24,P<0.05);观察组中位OS和中位PFS均显著长于对照组(11.9个月比8.3个月,7.5个月比4.7个月,t=2.56、3.01,均P<0.05);观察组治疗后KPS评分显著高于对照组、治疗前[(75.49±8.94)分比(68.65±7.06)分;(75.49±8.94)分比(62.23±6.34)分,t=2.78、5.11,均P<0.05);观察组治疗后凝血功能指标和肿瘤标志物水平均显著优于对照组、治疗前(t=3.14、2.67、3.59、7.31、4.89、4.02、4.70、9.21,2.44、2.60、3.20、3.15、3.78、4.06,均P<0.05);两组毒副作用发生率差异无统计学意义(P>0.05)。结论强化热疗辅助小剂量顺铂联合放疗治疗局部晚期NSCLC可有效控制病情进展,增加生存获益,提高生存质量,改善凝血功能,降低肿瘤标志物水平,且安全性值得认可。Objective To investigate the effect and safety of intensive hyperthermia combined with low-dose cisplatin plus radiotherapy in the treatment of patients with locally advanced NSCLC.Methods From January 2012 to December 2015,104 patients with locally advanced NSCLC were chosen in the Second People's Hospital of Weifang and randomly divided into two groups according to the digital table,with 52 patients in each group.The control group was given low-dose cisplatin plus radiotherapy,and the observation group was given intensive hyperthermia on the basis of control group.The ORR,DCR,median OS,median PFS,KPS score,the levels of coagulation function index and tumor markers before and after treatment and incidence of side effects in the two groups were compared.Results The DCR of the observation group was significantly higher than that of the control group(86.54%vs.69.23%,χ2=8.24,P<0.05).The median OS and median PFS of the observation group were significantly longer than those of the control group(11.9 months vs.8.3 months;7.5 months vs.4.7 months,t=2.56,3.01,P<0.05).The KPS scores after treatment of the observation group were significantly higher than those of the control group and before treatment[(75.49±8.94)points vs.(68.65±7.06)points;(75.49±8.94)points vs.(62.23±6.34)points,t=2.78,5.11,all P<0.05].The levels of coagulation function index and tumor markers after treatment of the observation group were significantly lower than those of the control group and before treatment(t=3.14,2.67,3.59,7.31;4.89,4.02,4.70,9.21;2.44,2.60,3.20;3.15,3.78,4.06;all P<0.05).There was no statistically significant difference in the incidence of side effects between the two groups(P>0.05).Conclusion Intensive hyperthermia combined with low-dose cisplatin plus radiotherapy in the treatment of patients with locally advanced NSCLC can efficiently control disease progress,increase survival benefits,higher quality of life,improve coagulation function,reduce the levels of tumor markers and possess satisfactory safety.

关 键 词：肺肿瘤 透热疗法 放射疗法 顺铂 

分 类 号：R734[医药卫生—肿瘤]